Introduction

The Koebner phenomenon refers to the appearance of new psoriasis plaques, which are red, scaly patches that can itch or burn, at sites of skin injury. The phenomenon was first discovered by Heinrich Koebner in 1872, when he observed that patients developed psoriatic lesions on scratched or damaged skin.¹ Recent research shows that about 25% of people with psoriasis experience Koebner reactions.² These reactions reveal how inherited genetic factors influence the way skin heals after trauma.

This article will identify the genetic variants most strongly linked to Koebner susceptibility, explain how those genes affect immune function and the skin’s protective barrier after injury, and discuss how this knowledge informs both prevention strategies and treatment options. It will give an understanding of which genetic markers carry the greatest risk, how these variants trigger extra inflammation at injury sites, and what steps patients and clinicians can take to reduce the chance of new lesions.

Genes associated with the Koebner phenomenon 

The Koebner phenomenon occurs because specific genetic variants, mainly the HLA-Cw6 allele in the PSORS1 locus, cause immune cells to overreact to skin injury. Additional genetic factors that regulate inflammatory signalling (including variants in CARD14 and IL23R) and genes involved in maintaining skin barrier integrity (notably the late cornified envelope, or LCE, cluster) further amplify this effect.^3,4,5 Together, these variants cause an excessive local immune response after even minor trauma, resulting in new psoriasis plaques at the site of injury.

Definition and clinical presentation

The Koebner phenomenon is formally defined as the development of new lesions, characteristic of a dermatological condition, on previously unaffected skin, following trauma.⁶

In psoriasis, these lesions are called plaques-raised, red, scaly patches of skin. Common triggers include mechanical injury, such as scratching or cuts, chemical irritation, medical procedures like injections or surgery, and even tight clothing or adhesives.⁷ Lesions typically appear between one and three weeks after the injury, though onset can range from a few days up to two months.² For patients and clinicians, recognising this pattern is vital, as it affects decisions about treatments and determines whether procedures should be delayed when psoriasis is active.⁸

Prevalence and impact on life 

Population studies estimate that 25–30% of psoriasis patients develop new plaques following trauma.² The likelihood of Koebner reactions is higher in chronic plaque psoriasis, the most common form of psoriasis, and lower in guttate or inverse variants of the condition.³ The unpredictability and severity of these reactions can significantly reduce the quality of life for individuals. People may avoid normal activities or necessary medical procedures for fear of triggering new lesions.⁹ New Koebner-induced plaques often resist topical treatments and may require more extreme systemic therapies, adding complexity and cost to care. Educating patients on gentle skin care, prompt wound management and risk-reducing behaviours is therefore essential to minimise both physical discomfort and emotional distress.¹⁰

Genetic architecture of psoriasis

Psoriasis is a polygenic disease, meaning the condition is influenced by the combined effect of multiple genes. Genome-wide association studies (GWAS) have identified over 80 genomic regions, or loci, that contribute to overall disease risk.¹ 

These loci fall into major categories: antigen presentation (the HLA region), innate immune activation (genes such as CARD14 and TRAF3IP2), adaptive immune regulation (IL23R, IL12B), and epidermal barrier formation (the LCE gene cluster).¹²

Many of these variants raise general psoriasis risk, but only a subset specifically affects the likelihood of Koebner reactions when the skin is injured. Identifying those Koebner-related loci clarifies why certain patients, but not others, develop injury-induced plaques.

PSORS1 and HLA-Cw6

The PSORS1 locus, located on chromosome 6p, accounts for approximately half of the heritable risk of developing psoriasis.³ Within PSORS1, the HLA-Cw6 allele is the single strongest genetic factor for both overall disease susceptibility and for Koebner responses.² HLA-Cw6 encodes a major histocompatibility complex class I molecule that presents peptides (small fragments of protein) from skin cells to CD8⁺ T lymphocytes. After skin injury, keratinocyte peptides bind more readily to HLA-Cw6, driving an aggressive T-cell-mediated immune reaction at the trauma site, which initiates plaque formation.² Family and case-control studies consistently show that individuals carrying HLA-Cw6 have a significantly higher rate of Koebner reactions than non-carriers.¹³

Non-HLA immune-regulating genes

Beyond HLA-Cw6, several non-HLA genes shape the intensity and duration of the inflammatory response following injury. Variants in CARD14 enhance NF-κB signalling in keratinocytes, leading to increased production of pro-inflammatory cytokines such as tumour necrosis factor-alpha and interleukin-6.⁴ Polymorphisms in IL23R skew T-cell differentiation toward the Th17 subtype, resulting in elevated interleukin-17 and interleukin-22 release, which perpetuate epidermal inflammation and proliferation.⁵ Additional loci, including TNIP1 and TRAF3IP2, modulate downstream pathways in the TNF and IL-17 axes, further influencing how robustly the immune system responds to skin damage.¹² Together, these genetic variants determine the threshold at which trauma will trigger new lesion formation.

Barrier-related loci: the LCE cluster

The late cornified envelope (LCE) gene cluster, located on chromosome 1q21, encodes proteins crucial for the final stages of keratinocyte differentiation and epidermal barrier formation.⁵ Deletion of LCE3B and LCE3C increases general psoriasis risk but does not alter the probability of Koebner reactions.⁵ This observation indicates that barrier defects alone permit easier entry of irritants and microbial products but require an immune-permissive genetic background, namely HLA-Cw6 and other immune-regulating variants, to trigger full plaque development after injury. The combination of a weak barrier and an overactive immune response thus underlies the Koebner phenomenon.

Cellular mechanisms following skin injury

When the skin is injured, keratinocytes and resident immune cells release a cocktail of cytokines and chemokines, including interleukin-17, interleukin-23 and tumour necrosis factor-alpha.¹⁴ These signalling molecules recruit additional immune cells; neutrophils, dendritic cells and T lymphocytes, to the injury site.

In genetically predisposed individuals, antigen presentation by HLA-Cw6 drives CD8⁺ T-cell activation more vigorously, while CARD14 and IL23R variants amplify local cytokine production. Barrier gene defects allow deeper penetration of irritants and microbial components, which further fuel the inflammatory milieu. This results in keratinocyte hyperproliferation, thickening of the epidermis and the characteristic red, scaly plaque that defines psoriasis and the Koebner reaction.

Environmental modifiers and treatment effects

Although genetic predisposition establishes susceptibility to Koebner reactions, environmental factors and systemic inflammation levels ultimately determine whether a lesion forms after injury. Minor trauma may not provoke a reaction if baseline immune activation is low. Conversely, factors such as smoking, obesity, psychological stress and infections elevate systemic cytokine levels, lowering the threshold for trauma-induced plaque development.¹⁵ 

Effective systemic therapies, particularly biologic agents targeting interleukin-17 (secukinumab, ixekizumab) or interleukin-23 (guselkumab, risankizumab), reduce baseline inflammation and markedly decrease the incidence of new Koebner lesions compared with older systemic treatments.⁶ By interrupting key cytokine pathways, these drugs blunt the post-injury inflammatory cascade and offer both therapeutic and preventive benefits for high-risk patients.

Clinical implications

Recognition of genetic risk factors for the Koebner phenomenon allows clinicians to personalise patient advice and management plans. Individuals known to carry HLA-Cw6 and other high-risk immune variants should be counselled to minimise skin trauma by adopting gentle hygiene practices, using soft clothing and delaying elective skin procedures when psoriasis is active.¹⁰ Prompt cleaning and light topical therapy, such as low-potency steroid creams or non-steroidal alternatives, applied immediately after minor cuts, can reduce local inflammation and prevent plaque initiation. 

In patients with frequent Koebner reactions, early initiation of biologic therapy may be considered to prevent both existing and trauma-induced lesions. Although genetic testing for HLA-Cw6 and related variants is not yet routine, emerging data suggest it could soon inform treatment timing and intensity.¹³

Future research directions

Future investigations should include large GWAS specifically designed to compare Koebner-positive and Koebner-negative psoriasis cohorts to uncover novel susceptibility loci.³ Integration of transcriptomic and single-cell sequencing data from injury-induced lesions could clarify which cell types and molecular pathways drive plaque initiation. Research into epigenetic modifications triggered by skin trauma may reveal mechanisms of “trained” inflammatory memory in the epidermis. Ultimately, these insights could lead to the development of targeted topical agents aimed at interrupting the Koebner cascade at its earliest stages, reducing reliance on systemic drugs.

FAQs

What is a psoriasis plaque?

A plaque is a raised, red, scaly patch of skin caused by rapid keratinocyte growth.³

How soon do Koebner lesions appear after injury?

They typically appear one to three weeks after the skin is injured.²

Can a small scratch trigger plaque?

Yes. About 25% of psoriasis patients develop new lesions at minor injury sites.²

Do all psoriasis types show Koebner reactions?

No. Chronic plaque psoriasis has a higher rate than guttate or inverse forms.³

What can patients do to reduce risk?

Clean and treat cuts promptly, use gentle cleansers, avoid scratching and manage overall inflammation through healthy habits and medication.⁶

Summary

The Koebner phenomenon results from the combined effects of genetic variants that amplify immune responses and compromise barrier integrity after skin injury. The primary risk factor is the HLA-Cw6 allele in the PSORS1 locus, supported by non-HLA genes such as CARD14 and IL23R and by barrier-related loci in the LCE cluster. Injury triggers an excessive local release of inflammatory cytokines, which directly leads to the formation of new psoriasis plaques at the trauma site. Understanding these mechanisms supports personalised prevention strategies, gentle skin care, avoidance of unnecessary trauma and prompt wound management, and informs the use of targeted biologic therapies that reduce both existing and trauma-induced lesions.